**Role of LC-MS in high-throughput screening of biomarker**

Shivanshu Gangwar1\*, Rohit Kumar2, Mandeep Yadav3, Himanshi Rathaur4, Rizwan Ahmad5

**Affiliations**

**1**Shri Ram Murti Smarak College of Engineering and Technology, Ram Murti Puram, Bareilly-Nainital Highway, Bhojipura, Bareilly-243202, UP, India

**2** Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow-226025

**3**SGT College of Pharmacy, SGT University, Gurgaon-Badli Road Chandu, Budhera, Gurugram, Haryana-122505.

**4**College of Pharmacy, Shivalik Campus, Sihniwala, Shimla Road, Dehradun- 248197

**5**Azad Institute of Pharmacy and Research, Lucknow, Azadpuram, adjacent CRPF camp, Bijnaur, Lucknow -226002.

**\*Corresponding Author:** Shivanshu Gangwar

**Affiliation:** Shri Ram Murti Smarak College of Engineering and Technology Bareilly

**E-mail:** shivagangwar007@gmail.com

**IIP Login ID:** shivagangwar007@gmail.com

**Password:** shivanshu1104

# Abstract

The identification and quantification of biomarkers play a crucial role in biomedical research and clinical diagnostics. High throughput screening (HTS) methods have emerged as powerful tools for rapidly assessing numerous biomolecules across large sample sets. Liquid chromatography-mass spectrometry (LC-MS) has become a leading technology in biomarker analysis due to its unparalleled sensitivity, selectivity, and versatility. This abstract aim to explore the pivotal role of LC-MS in HTS of biomarker analysis. We begin by highlighting the importance of biomarkers as key indicators of biological processes and disease states, emphasizing the pressing need for efficient and accurate screening methods. Next, we delve into the principles of LC-MS and how it synergistically combines liquid chromatography's separation capabilities with mass spectrometry's analytical power, enabling the identification and quantification of a wide range of biomolecules, including proteins, peptides, metabolites, and lipids. The advantages of LC-MS in HTS become apparent when discussing its ability to analyze large sample cohorts rapidly. Through automation and high-resolution instrumentation, LC-MS streamlines the analysis of thousands of samples, providing researchers with an unprecedented depth of biomarker data. Furthermore, LC-MS enables the simultaneous measurement of multiple analytes, fostering a comprehensive understanding of complex biological processes and disease mechanisms. This abstract also addresses the challenges and advancements in LC-MS technology, such as enhancing sensitivity and reproducibility, minimizing sample preparation time, and implementing robust data analysis pipelines. Additionally, we touch upon the integration of LC-MS with other omics technologies, such as genomics and proteomics, to leverage the collective power of multiple analytical approaches. The application of LC-MS in HTS of biomarker analysis has found significant utility in various fields, including cancer research, pharmacokinetic studies, and personalized medicine. The ability to rapidly screen and validates potential biomarkers facilitates early disease detection, patient stratification, and monitoring of treatment responses, leading to improved patient outcomes. In conclusion, LC-MS has revolutionized biomarker analysis by playing a pivotal role in HTS workflows. Its unparalleled sensitivity, high throughput capacity, and compatibility with diverse biomolecules have significantly advanced our understanding of biological systems and disease states. As technology continues to evolve, LC-MS will undoubtedly remain at the forefront of biomarker research, providing invaluable insights for future biomedical and clinical applications.

**Keywords:** LC-MS, High throughput screening, Biomarker analysis, Liquid chromatography-mass spectrometry, Biomolecules, Proteins, Peptides, Metabolites, Genomics, Proteomics.

# Introduction

The rapid advancement of biomedical research and clinical diagnostics has underscored the critical role of biomarkers in unraveling complex biological processes and disease states. Biomarkers, measurable indicators of normal or pathological biological processes, offer invaluable insights into health status, disease progression, and treatment responses. To harness the potential of biomarkers effectively, high throughput screening (HTS) methods have emerged as indispensable tools for swiftly analyzing a vast array of biomolecules across large sample sets. Among the various analytical techniques, liquid chromatography-mass spectrometry (LC-MS) has taken center stage due to its exceptional sensitivity, selectivity, and versatility (Hollis and Horst, 2007; Rao Gajula and Nanjappan, 2021; Sun et al., 2005).

Biomarker analysis has become a cornerstone of modern research, allowing scientists to decipher the intricacies of physiological systems and diseases with unprecedented precision. The ability to identify and quantify biomolecules, such as proteins, peptides, metabolites, and lipids, not only contributes to a deeper understanding of biological processes but also holds tremendous potential for clinical applications. From detecting early disease onset to personalizing medical interventions, biomarkers have revolutionized the landscape of healthcare, making their accurate and efficient analysis a paramount goal for researchers and clinicians alike (Camperi et al., 2021; Hollis and Horst, 2007; Tuli and Ressom, 2009).

In response to the growing demand for expeditious biomarker analysis, high throughput screening has emerged as a transformative technology capable of assessing thousands of samples in a remarkably short time frame. HTS methods facilitate the rapid exploration of large sample cohorts, providing comprehensive datasets that empower researchers to discern patterns, identify novel biomarkers, and validate their functional significance. The integration of HTS into biomarker research has propelled the field forward, enabling the discovery of diagnostic, prognostic, and predictive biomarkers that are paving the way for personalized medicine and targeted therapies (Gautam et al., 2023; Rao Gajula and Nanjappan, 2021; Zhou et al., 2012).

Amid the diverse array of analytical technologies available, liquid chromatography-mass spectrometry has emerged as a leading method in biomarker analysis. LC-MS combines two powerful analytical techniques, liquid chromatography and mass spectrometry, to offer enhanced separation and detection capabilities. Liquid chromatography employs various stationary phases to separate biomolecules based on their physicochemical properties, such as size, polarity, and charge, while mass spectrometry measures the mass-to-charge ratio of ions, providing high-resolution identification and quantification of analytes. This synergistic combination empowers LC-MS to analyze a wide range of biomolecules with unparalleled sensitivity and selectivity (Gaurav, 2022; Gaurav et al., 2023, 2022; Gautam, 2022).

The sensitivity of LC-MS allows for the detection of trace amounts of biomolecules, even in complex biological matrices, enhancing the likelihood of identifying low-abundance biomarkers with significant clinical relevance. Additionally, LC-MS exhibits exceptional selectivity, distinguishing between closely related molecules based on their mass-to-charge ratios, thereby minimizing false positives and ensuring precise biomarker identification. This level of accuracy is vital when exploring complex biological systems, where a multitude of molecules coexist, necessitating a method capable of disentangling intricate molecular networks. One of the fundamental advantages of LC-MS in HTS workflows lies in its capacity for high throughput analysis. Automation has revolutionized the field, enabling researchers to process large sample cohorts efficiently and consistently, while maintaining the reproducibility of results. The integration of robotics, liquid handling systems, and data processing software streamlines the entire analytical process, reducing the time required for analysis and minimizing potential sources of human error (Gaurav, 2022; Khan et al., 2021).

Furthermore, LC-MS's versatility extends beyond single analyte detection, enabling multiplexed analysis of multiple biomolecules in a single run. This capability is particularly valuable when exploring complex diseases or understanding the interplay between different biomolecules within biological systems. By simultaneously quantifying various biomarkers, LC-MS provides a holistic view of disease pathology and drug response, ultimately guiding more informed clinical decision-making. Despite the numerous advantages, LC-MS-based biomarker analysis also presents challenges that demand continuous innovation. Improving sensitivity and reducing limits of detection remains a primary focus, as many biomarkers occur at ultra-low concentrations in biological samples. Advancements in sample preparation techniques and pre-analytical workflows have sought to mitigate these challenges, ensuring reliable and accurate measurements. Additionally, the vast amounts of data generated by HTS methodologies necessitate sophisticated data analysis pipelines and bioinformatics tools. Extracting meaningful insights from complex datasets requires robust statistical analysis, bioinformatics algorithms, and machine learning approaches, facilitating the discovery of relevant biomarker patterns and correlations (Gaurav et al., 2020; Ibrahim et al., 2021; Parveen et al., 2020; Zahiruddin et al., 2021).

The integration of LC-MS with other omics technologies, such as genomics and proteomics, is another burgeoning area of research. By amalgamating data from multiple analytical platforms, researchers gain a more comprehensive understanding of disease mechanisms and potential therapeutic targets. This multi-omics approach offers a holistic view of the molecular landscape, fostering a systems biology perspective that transcends the reductionist approach of studying individual biomolecules (Deseo et al., 2020). Hence, biomarker analysis and high throughput screening have revolutionized biomedical research and clinical diagnostics, propelling personalized medicine and precision healthcare to the forefront of modern healthcare practices. Liquid chromatography-mass spectrometry has emerged as a pivotal technology in this pursuit, offering exceptional sensitivity, selectivity, and throughput capacity. From cancer research to pharmacokinetics and beyond, LC-MS has enabled the identification, quantification, and validation of diverse biomarkers critical for understanding disease processes and guiding therapeutic interventions. As technology continues to evolve, the integration of LC-MS with other cutting-edge methodologies promises to further advance biomarker research, unlocking new frontiers in biomedical science and healthcare delivery (Ahmad et al., 2021; Khan et al., 2022a, 2022b).

# Review findings

Liquid chromatography-mass spectrometry (LC-MS) is a powerful analytical technique that combines the separation capabilities of liquid chromatography (LC) with the high-resolution detection and quantification abilities of mass spectrometry (MS). This synergistic combination has made LC-MS an indispensable tool in biomarker analysis, enabling the identification and quantification of a wide range of biomolecules with unparalleled sensitivity, selectivity, and throughput capacity.

# Role of LC-MS in biomarkers analysis

* 1. **Proteins and Peptides**

One of the most prominent applications of LC-MS in biomarker analysis is in the field of proteomics. Proteins play crucial roles in various biological processes, and their expression levels, post-translational modifications, and interactions provide vital insights into the functioning of cells and tissues. LC-MS allows for the analysis of complex protein mixtures, such as those derived from tissues or biofluids, by first separating the proteins based on their physicochemical properties using liquid chromatography and then subjecting the separated peptides to mass spectrometric detection. Modern LC-MS systems, including high-resolution mass spectrometers and advanced fragmentation techniques, enable the identification and characterization of thousands of proteins in a single experiment, making it a valuable tool in biomarker discovery studies (Alqahtani et al., 2022; Muir et al., 2011; Singh et al., 2021).

## Metabolites

Metabolites are small molecules that are intermediates or end products of cellular metabolic pathways. They serve as direct indicators of cellular activity and can provide valuable information about the physiological status of cells and tissues. LC-MS-based metabolomics allows researchers to identify and quantify metabolites in complex biological samples, such as urine, plasma, and tissue extracts. By comparing the metabolite profiles of healthy and diseased samples, potential biomarkers associated with specific diseases or metabolic states can be identified. LC-MS has found applications in various fields, including clinical diagnostics, drug development, and understanding disease mechanisms (Gaurav, 2022; Gautam et al., 2023).

## Lipids

Lipids are a diverse group of biomolecules that serve as essential components of cellular membranes and are involved in various cellular processes, including signaling and energy storage. Lipidomics, the study of lipids in biological systems, has gained significant momentum with the development of LC-MS methodologies capable of profiling lipid classes and individual lipid species. LC-MS allows researchers to determine lipid composition and quantify changes in lipid levels, offering valuable information on lipid metabolism and its role in health and disease (Gaurav, 2022; Guenette et al., 2006).

## Small Molecules

LC-MS is widely used in the analysis of small molecules, including drugs and their metabolites, environmental contaminants, and endogenous metabolites. For pharmaceutical research, LC-MS plays a pivotal role in drug development, aiding in drug metabolism studies, pharmacokinetics, and bioavailability assessments. LC-MS is also employed in environmental monitoring to detect and quantify contaminants in various matrices, such as water and soil. Additionally, LC-MS-based metabolite profiling provides insights into endogenous metabolic pathways and has applications in clinical research, nutrition, and personalized medicine (Lai et al., 2015; Singh et al., 2021).

## Peptidomics

Peptidomics focuses on the identification and quantification of endogenous peptides, which serve as important signaling molecules and regulators of physiological processes. These peptides are often short-lived and present at low concentrations, making LC-MS a suitable technique for their analysis. By utilizing LC-MS, researchers can identify and characterize bioactive peptides, providing valuable information about their roles in various biological functions, such as neurotransmission, immune response, and cardiovascular regulation (Huang et al., 2022; Miedzybrodzka et al., 2020; Siddiqui et al., 2017; Sigdel et al., 2014).

## Glycans

Glycans are carbohydrate chains that are covalently attached to proteins and lipids, influencing various cellular processes, including protein folding, cell adhesion, and immune response. The analysis of glycans is particularly challenging due to their structural complexity and heterogeneity. LC-MS has become a prominent technique in glycomics, allowing for the identification and quantification of glycans in biological samples. By combining LC with MS, researchers can achieve higher separation efficiency and sensitivity, enabling the detailed analysis of glycan structures and their potential roles as biomarkers (Dolashka et al., 2020; Gray et al., 2020, 2016; Manz et al., 2022).

## Modified Nucleotides

LC-MS plays a vital role in the analysis of modified nucleotides, which are altered forms of DNA and RNA bases resulting from epigenetic modifications or DNA damage. These modifications are crucial in regulating gene expression and have implications in various biological processes, including development and disease. LC-MS-based approaches allow researchers to identify and quantify modified nucleotides in nucleic acid samples, providing insights into epigenetic changes and potential biomarkers associated with specific disease states or environmental exposures (Crittenden et al., 2023; Saha et al., 2020; Taoka et al., 2015; Tozaki et al., 2018).

## Isotopes and Stable-Isotope Labeled Compounds

LC-MS is frequently used in quantitative analysis, and stable-isotope labeling techniques have become essential tools in biomarker studies. Stable isotopes are non-radioactive isotopes of elements that can be incorporated into biomolecules as internal standards. By introducing stable-isotope labeled compounds into samples and using LC-MS for quantification, researchers can accurately determine the concentration of target biomolecules in complex matrices. This approach ensures precise and reliable quantification of biomarkers, particularly in metabolomics and pharmacokinetic studies (Aouri et al., 2013; Burton and Wadsworth, 2007; Mameli et al., 2022).

## Xenobiotics and Metabolites

LC-MS is extensively used in drug metabolism and pharmacokinetics studies, enabling the identification and quantification of drugs and their metabolites in biological samples. Understanding the fate of drugs in the body is critical for drug development and optimization, as well as for monitoring therapeutic drug levels in patients. LC-MS also plays a role in the analysis of xenobiotics and environmental contaminants, facilitating their detection and quantification in various samples to assess exposure levels and potential health risks (Cancelada et al., 2022; Chavez Soria et al., 2019; Matysik et al., 2021; Siless et al., 2018).

## Biomarkers of Disease

LC-MS has significantly contributed to the discovery and validation of biomarkers associated with specific diseases or pathological conditions. By analyzing complex biological samples, such as blood, urine, or tissue extracts, LC-MS allows for the identification of disease-specific biomolecules, including proteins, metabolites, and lipids. These biomarkers can serve as diagnostic, prognostic, or predictive indicators, aiding in early disease detection, disease monitoring, and treatment response assessments. LC-MS-based biomarker discovery has promising applications in cancer research, cardiovascular diseases, neurodegenerative disorders, and other clinical fields (Chao et al., 2021; Dey et al., 2019; Maekawa and Mano, 2022; Ponzini et al., 2022).

## Natural Products

Natural products are biologically active compounds derived from plants, animals, fungi, and microorganisms. They have served as a rich source of pharmacologically active molecules for drug discovery and development. LC-MS plays a crucial role in the analysis of natural products, enabling researchers to identify and characterize bioactive compounds with potential therapeutic applications. By profiling natural product extracts using LC-MS, researchers can pinpoint the presence of specific compounds and assess their potential as lead candidates for drug development.

In conclusion, liquid chromatography-mass spectrometry (LC-MS) is a versatile and indispensable analytical technique for biomarker analysis. From proteins and peptides to metabolites, lipids, and modified nucleotides, LC-MS allows researchers to delve into the molecular complexity of biological systems and identify potential biomarkers associated with various physiological and disease states. The development of high-resolution mass spectrometers, advanced chromatographic techniques, and sophisticated data analysis tools has further expanded the capabilities of LC-MsS, making it a cornerstone technology in biomedical research, clinical diagnostics, and drug development. As technology continues to evolve, LC-MS will undoubtedly play an even more prominent role in biomarker discovery, contributing to advances in personalized medicine, disease diagnostics, and therapeutic interventions.

**Table 1:** The role of LC-MS in high-throughput screening of biomarkers along with suitable examples

|  |  |  |
| --- | --- | --- |
| **Biomolecule Type** | **Role of LC-MS in HTS of Biomarker Analysis** | **Examples** |
| Proteins and Peptides | - Identifying and quantifying proteins and peptides in complex mixtures | Example: LC-MS is used to identify specific protein biomarkers in blood samples for early cancer detection. |
| - High-resolution analysis for protein isoforms and post-translational modifications | Example: LC-MS/MS is utilized to study phosphorylation sites in proteins associated with Alzheimer's disease. |
| - Enabling large-scale proteomic studies to discover disease-specific biomarkers | Example: LC-MS-based proteomics identifies candidate biomarkers for heart failure in plasma samples. |
| - Facilitating protein-protein interaction studies for network analysis | Example: LC-MS is employed to investigate protein-protein interactions in a signaling pathway in cells. |
| Metabolites | - Profiling metabolic pathways and understanding disease-related changes | Example: LC-MS-based metabolomics reveals metabolic alterations in diabetes mellitus. |
| - Quantifying small molecules for personalized medicine and disease monitoring | Example: LC-MS measures drug metabolites in patient plasma to optimize medication dosages. |
| - Identifying biomarkers for metabolic diseases and drug responses | Example: LC-MS identifies metabolic biomarkers associated with drug-induced liver injury. |
| - Enabling pharmacokinetic studies and drug metabolism analysis | Example: LC-MS quantifies drug levels in blood samples to assess drug clearance rates. |
| Lipids | - Identifying and quantifying lipid species in biological samples | Example: LC-MS lipidomics characterizes lipid profiles in cancer tissue for biomarker discovery. |
| - Linking lipidomics to diseases like obesity, cardiovascular disorders, and cancer | Example: LC-MS identifies specific lipids associated with coronary artery disease in blood samples. |
| - Understanding lipid metabolism and its implications in cellular function | Example: LC-MS lipidomics reveals changes in lipid metabolism during cell differentiation. |
| - Identifying lipid biomarkers for various diseases and therapeutic responses | Example: LC-MS identifies lipid biomarkers for evaluating treatment response in multiple sclerosis. |
| Modified Nucleotides | - Detecting epigenetic changes and DNA/RNA base modifications | Example: LC-MS detects methylated DNA bases in cancer cells to study epigenetic changes. |
| - Investigating their role in gene regulation and disease development | Example: LC-MS characterizes RNA modifications to understand their role in cellular processes. |
| - Identifying DNA damage and its association with environmental exposures | Example: LC-MS quantifies DNA adducts as biomarkers of exposure to environmental carcinogens. |
| - Discovering potential biomarkers for cancer and other diseases | Example: LC-MS identifies modified nucleotides as potential biomarkers for breast cancer. |
| Small Molecules | - Quantifying drugs and their metabolites for pharmacokinetic studies | Example: LC-MS measures drug levels in blood to assess drug distribution and clearance. |
| - Detecting environmental contaminants and toxins | Example: LC-MS identifies pesticide residues in food samples to ensure food safety. |
| - Analyzing endogenous metabolites for disease biomarker discovery | Example: LC-MS-based metabolomics identifies metabolic biomarkers for liver disease. |
| - Understanding metabolic pathways and their regulation | Example: LC-MS quantifies metabolites in a metabolic pathway to study enzyme activity regulation. |
| Peptidomics | - Identifying and characterizing endogenous peptides | Example: LC-MS-based peptidomics discovers novel bioactive peptides in brain tissue. |
| - Exploring their roles as signaling molecules and disease regulators | Example: LC-MS identifies neuropeptides associated with pain signaling in the nervous system. |
| - Discovering novel bioactive peptides for drug development | Example: LC-MS identifies bioactive peptides in venoms for potential therapeutic applications. |
| - Studying neuropeptides and hormone-derived peptides | Example: LC-MS characterizes hormone-derived peptides in blood for endocrine disorder research. |
| Glycans | - Analyzing the structural complexity of glycans | Example: LC-MS analyzes glycans on proteins for understanding cell surface receptor interactions. |
| - Linking glycomics to diseases and biological processes | Example: LC-MS glycomics identifies altered glycosylation patterns in cancer cells. |
| - Identifying glycan biomarkers for cancer and other diseases | Example: LC-MS identifies specific glycan biomarkers in serum for cancer diagnosis. |
| - Investigating glycan-mediated cellular interactions | Example: LC-MS reveals glycan ligands involved in pathogen recognition by immune cells. |
| Isotopes and Stable-Isotope Labeled Compounds | - Accurate quantification of biomarkers using stable-isotope internal standards | Example: LC-MS quantifies drug metabolites using stable-isotope labeled internal standards. |
| - Ensuring reliable and reproducible measurements in metabolomics and pharmacokinetics | Example: LC-MS quantifies metabolites in biological samples with stable-isotope labeled standards. |
| - Improving data accuracy and comparability in biomarker studies | Example: LC-MS uses stable-isotope labeled peptides to standardize quantitative proteomics experiments. |
| - Enabling precise determination of drug concentrations in patient samples | Example: LC-MS quantifies drug levels in blood to optimize drug dosing in patients. |
| Biomarkers of Disease | - Discovery of disease-specific biomarkers in various biological samples | Example: LC-MS identifies protein biomarkers in cerebrospinal fluid for diagnosing Alzheimer's disease. |
| - Early detection and diagnosis of diseases using targeted LC-MS assays | Example: LC-MS identifies specific metabolites in blood for early detection of kidney disease. |
| - Validation of biomarkers for disease prognosis and treatment response | Example: LC-MS quantifies protein biomarkers in plasma to assess treatment response in cancer patients. |
| - Enabling precision medicine and personalized treatment strategies | Example: LC-MS-based profiling of cancer tissue guides personalized therapeutic approaches. |
| Natural Products | - Identifying and characterizing bioactive compounds from natural sources | Example: LC-MS identifies bioactive compounds in medicinal plants for drug discovery. |
| - Screening for potential lead molecules in drug discovery and development | Example: LC-MS identifies novel bioactive compounds from marine organisms for drug development. |
| - Determining the composition and quality of natural product extracts | Example: LC-MS assesses the chemical profile of herbal extracts for quality control and standardization. |
| - Assessing the biological activity and therapeutic potential of natural products | Example |

Top of Form

# Conclusion

In conclusion, liquid chromatography-mass spectrometry (LC-MS) has emerged as a pivotal technology in high-throughput screening of biomarkers. Its exceptional sensitivity, selectivity, and versatility have revolutionized biomarker analysis, enabling the identification and quantification of a diverse array of biomolecules, including proteins, peptides, metabolites, lipids, and modified nucleotides. LC-MS's ability to rapidly analyze large sample cohorts and its capacity for multiplexed analysis have propelled biomarker research to new heights, facilitating the discovery and validation of diagnostic, prognostic, and predictive biomarkers. Through its integration with other omics technologies, LC-MS has provided a holistic view of complex biological systems and disease mechanisms. As a result, LC-MS plays a pivotal role in advancing personalized medicine, early disease detection, patient stratification, and drug development. Continual advancements in LC-MS technology and data analysis methodologies will undoubtedly strengthen its impact in biomarker research, paving the way for more precise and effective healthcare strategies.

**Conflict of interest**

Authors declare no conflict of interest.

**Acknowledgement**

Authors would like to acknowledge Dr. Gaurav, IIMT college of medical sciences, IIMT university, Meerut, Uttar Pradesh-250001 for conceptualization and drafting the study.

**References**

Ahmad, S., Zahiruddin, S., Parveen, B., Basist, P., Parveen, A., Gaurav, Parveen, R., Ahmad, M., 2021. Indian Medicinal Plants and Formulations and Their Potential Against COVID-19–Preclinical and Clinical Research. Front. Pharmacol. https://doi.org/10.3389/fphar.2020.578970

Alqahtani, M.J., Mostafa, S.A., Hussein, I.A., Elhawary, S., Mokhtar, F.A., Albogami, S., Tomczyk, M., Batiha, G.E.S., Negm, W.A., 2022. Metabolic Profiling of Jasminum grandiflorum L. Flowers and Protective Role against Cisplatin-Induced Nephrotoxicity: Network Pharmacology and In Vivo Validation. Metabolites 12. https://doi.org/10.3390/metabo12090792

Aouri, M., Calmy, A., Hirschel, B., Telenti, A., Buclin, T., Cavassini, M., Rauch, A., Decosterd, L.A., 2013. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. J. Mass Spectrom. https://doi.org/10.1002/jms.3200

Burton, A.J., Wadsworth, A.H., 2007. Stable isotopic labelling of heterocyclic compounds, in: Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.1235

Camperi, J., Goyon, A., Guillarme, D., Zhang, K., Stella, C., 2021. Multi-dimensional LC-MS: The next generation characterization of antibody-based therapeutics by unified online bottom-up, middle-up and intact approaches. Analyst 146, 747–769. https://doi.org/10.1039/d0an01963a

Cancelada, L., Torres, R.R., Garrafa Luna, J., Dorrestein, P.C., Aluwihare, L.I., Prather, K.A., Petras, D., 2022. Assessment of styrene-divinylbenzene polymer (PPL) solid-phase extraction and non-targeted tandem mass spectrometry for the analysis of xenobiotics in seawater. Limnol. Oceanogr. Methods. https://doi.org/10.1002/lom3.10470

Chao, M.R., Evans, M.D., Hu, C.W., Ji, Y., Møller, P., Rossner, P., Cooke, M.S., 2021. Biomarkers of nucleic acid oxidation – A summary state-of-the-art. Redox Biol. https://doi.org/10.1016/j.redox.2021.101872

Chavez Soria, N.G., Bisson, M.A., Atilla-Gokcumen, G.E., Aga, D.S., 2019. High-resolution mass spectrometry-based metabolomics reveal the disruption of jasmonic pathway in Arabidopsis thaliana upon copper oxide nanoparticle exposure. Sci. Total Environ. https://doi.org/10.1016/j.scitotenv.2019.07.249

Crittenden, C.M., Lanzillotti, M.B., Chen, B., 2023. Top-Down Mass Spectrometry of Synthetic Single Guide Ribonucleic Acids Enabled by Facile Sample Clean-Up. Anal. Chem. https://doi.org/10.1021/acs.analchem.2c03030

Deseo, M.A., Elkins, A., Rochfort, S., Kitchen, B., 2020. Antioxidant activity and polyphenol composition of sugarcane molasses extract. Food Chem. https://doi.org/10.1016/j.foodchem.2020.126180

Dey, K.K., Wang, H., Niu, M., Bai, B., Wang, X., Li, Y., Cho, J.H., Tan, H., Mishra, A., High, A.A., Chen, P.C., Wu, Z., Beach, T.G., Peng, J., 2019. Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s disease. Clin. Proteomics. https://doi.org/10.1186/s12014-019-9237-1

Dolashka, P., Daskalova, A., Dolashki, A., Voelter, W., 2020. De novo structural determination of the oligosaccharide structure of hemocyanins from molluscs. Biomolecules. https://doi.org/10.3390/biom10111470

Gaurav, 2022. GC–MS metabolomics and network pharmacology-based investigation of molecular mechanism of identified metabolites from Tinospora cordifolia (Willd.) miers for the treatment of kidney diseases. Pharmacogn. Mag. 18, 548–558. https://doi.org/10.4103/pm.pm\_582\_21

Gaurav, Khan, M.U., Basist, P., Zahiruddin, S., Ibrahim, M., Parveen, R., Krishnan, A., Ahmad, S., 2022. Nephroprotective potential of Boerhaavia diffusa and Tinospora cordifolia herbal combination against diclofenac induced nephrotoxicity. South African J. Bot. 000. https://doi.org/10.1016/j.sajb.2022.01.038

Gaurav, Sharma, I., Khan, M.U., Zahiruddin, S., Basist, P., Ahmad, S., 2023. Multi-Mechanistic and Therapeutic Exploration of Nephroprotective Effect of Traditional Ayurvedic Polyherbal Formulation Using In Silico, In Vitro and In Vivo Approaches. Biomedicines 11. https://doi.org/10.3390/biomedicines11010168

Gaurav, Zahiruddin, S., Parveen, B., Ibrahim, M., Sharma, I., Sharma, S., Sharma, A.K., Parveen, R., Ahmad, S., 2020. TLC-MS bioautography-based identification of free-radical scavenging, α‑amylase, and α‑glucosidase inhibitor compounds of antidiabetic tablet BGR-34. ACS Omega. https://doi.org/10.1021/acsomega.0c02995

Gautam, G., 2022. Network Pharmacology-Based Validation of Traditional Therapeutic Claim of Momordica Charantiain Alleviating Diabetic Nephropathy. J. CAM Res. Prog. 1, 1–10.

Gautam, G., Parveen, R., Ahmad, S., 2023. LC-MS-based Metabolomics of Medicinal Plants, in: Omics Studies of Medicinal Plants. https://doi.org/10.1201/9781003179139-9

Gray, C.J., Compagnon, I., Flitsch, S.L., 2020. Mass spectrometry hybridized with gas-phase InfraRed spectroscopy for glycan sequencing. Curr. Opin. Struct. Biol. https://doi.org/10.1016/j.sbi.2019.12.014

Gray, C.J., Thomas, B., Upton, R., Migas, L.G., Eyers, C.E., Barran, P.E., Flitsch, S.L., 2016. Applications of ion mobility mass spectrometry for high throughput, high resolution glycan analysis. Biochim. Biophys. Acta - Gen. Subj. https://doi.org/10.1016/j.bbagen.2016.02.003

Guenette, S.A., Beaudry, F., Marier, J.F., Vachon, P., 2006. Pharmacokinetics and anesthetic activity of eugenol in male Sprague-Dawley rats. J. Vet. Pharmacol. Ther. https://doi.org/10.1111/j.1365-2885.2006.00740.x

Hollis, B.W., Horst, R.L., 2007. The assessment of circulating 25(OH)D and 1,25(OH)2D: Where we are and where we are going. J. Steroid Biochem. Mol. Biol. https://doi.org/10.1016/j.jsbmb.2006.11.004

Huang, Y.P., Robinson, R.C., Dias, F.F.G., de Moura Bell, J.M.L.N., Barile, D., 2022. Solid-Phase Extraction Approaches for Improving Oligosaccharide and Small Peptide Identification with Liquid Chromatography-High-Resolution Mass Spectrometry: A Case Study on Proteolyzed Almond Extract. Foods. https://doi.org/10.3390/foods11030340

Ibrahim, M., Parveen, B., Zahiruddin, S., Gautam, G., Parveen, R., Ahmed, M., Arun, K., Sayeed, G., 2021. Analysis of polyphenols in Aegle marmelos leaf and ameliorative efficacy against diabetic mice through restoration of antioxidant and anti- ­ inflammatory status 1–15. https://doi.org/10.1111/jfbc.13852

Khan, A., Zahiruddin, S., Ibrahim, M., Basist, P., Gaurav, Parveen, R., Umar, S., Ahmad, S., 2021. Thin layer chromatography-mass spectrometry bioautographic identification of free radical scavenging compounds and metabolomic profile of Carica papaya linn. fruit and seeds using high-performance thin-layer chromatography, gas chromatography-mass spectro. Pharmacogn. Mag. https://doi.org/10.4103/pm.pm\_326\_20

Khan, M.U., Gaurav, Zahiruddin, S., Basist, P., Krishnan, A., Parveen, R., Ahmad, S., 2022a. Nephroprotective potential of Sharbat-e-Bazoori Motadil (sugar-free) in HEK-293 cells and Wistar rats against cisplatin induced nephrotoxicity. J. King Saud Univ. - Sci. 34, 101839. https://doi.org/10.1016/j.jksus.2022.101839

Khan, M.U., Gautam, G., Jan, B., Zahiruddin, S., Parveen, R., Ahmad, S., 2022b. Vitamin D from Vegetable VV Sources: Hope for the Future. Phytomedicine Plus. https://doi.org/10.1016/j.phyplu.2022.100248

Lai, K.M., Cheng, Y.Y., Tsai, T.H., 2015. Integrated LC-MS/MS analytical systems and physical inspection for the analysis of a botanical herbal preparation. Molecules. https://doi.org/10.3390/molecules200610641

Maekawa, M., Mano, N., 2022. Searching, Structural Determination, and Diagnostic Performance Evaluation of Biomarker Molecules for Niemann–Pick Disease Type C Using Liquid Chromatography/Tandem Mass Spectrometry. Mass Spectrom. https://doi.org/10.5702/massspectrometry.A0111

Mameli, M., Franchi, J., Calusi, G., Deken, M.A., Johnson, Z., van der Veen, L., Lahn, M., Vezzelli, A., Cardin, R., Greco, A., Breda, M., 2022. Validation of an LC–MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial. J. Pharm. Biomed. Anal. https://doi.org/10.1016/j.jpba.2022.114829

Manz, C., Mancera-Arteu, M., Zappe, A., Hanozin, E., Polewski, L., Giménez, E., Sanz-Nebot, V., Pagel, K., 2022. Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry. Anal. Chem. https://doi.org/10.1021/acs.analchem.2c00783

Matysik, S., Krautbauer, S., Liebisch, G., Schött, H.F., Kjølbæk, L., Astrup, A., Blachier, F., Beaumont, M., Nieuwdorp, M., Hartstra, A., Rampelli, S., Pagotto, U., Iozzo, P., 2021. Short-chain fatty acids and bile acids in human faeces are associated with the intestinal cholesterol conversion status. Br. J. Pharmacol. https://doi.org/10.1111/bph.15440

Miedzybrodzka, E.L., Foreman, R.E., Galvin, S.G., Larraufie, P., George, A.L., Goldspink, D.A., Reimann, F., Gribble, F.M., Kay, R.G., 2020. Organoid Sample Preparation and Extraction for LC-MS Peptidomics. STAR Protoc. https://doi.org/10.1016/j.xpro.2020.100164

Muir, R.M., Ibáñez, A.M., Uratsu, S.L., Ingham, E.S., Leslie, C.A., McGranahan, G.H., Batra, N., Goyal, S., Joseph, J., Jemmis, E.D., Dandekar, A.M., 2011. Mechanism of gallic acid biosynthesis in bacteria (Escherichia coli) and walnut (Juglans regia). Plant Mol. Biol. https://doi.org/10.1007/s11103-011-9739-3

Parveen, R., Khan, N., Zahiruddin, S., Ibrahim, M., Anjum, V., Parveen, B., Khan, M.A., 2020. TLC-Bioautographic Evaluation for High-Throughput Screening and Identification of Free Radical Scavenging and Antidiabetic Compounds from Traditional Unani Medicinal Plant: Citrullus colocynthis Schrad. J. AOAC Int. https://doi.org/10.5740/jaoacint.19-0287

Ponzini, E., Santambrogio, C., De Palma, A., Mauri, P., Tavazzi, S., Grandori, R., 2022. Mass spectrometry-based tear proteomics for noninvasive biomarker discovery. Mass Spectrom. Rev. https://doi.org/10.1002/mas.21691

Rao Gajula, S.N., Nanjappan, S., 2021. Metabolomics: a recent advanced omics technology in herbal medicine research, in: Medicinal and Aromatic Plants. pp. 97–117. https://doi.org/10.1016/b978-0-12-819590-1.00005-7

Saha, A., Duchambon, P., Masson, V., Loew, D., Bombard, S., Teulade-Fichou, M.P., 2020. Nucleolin Discriminates Drastically between Long-Loop and Short-Loop Quadruplexes. Biochemistry. https://doi.org/10.1021/acs.biochem.9b01094

Siddiqui, G., Srivastava, A., Russell, A.S., Creek, D.J., 2017. Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin-resistant plasmodium falciparum. J. Infect. Dis. https://doi.org/10.1093/infdis/jix156

Sigdel, T.K., Nicora, C.D., Hsieh, S.C., Dai, H., Qian, W.J., Camp, D.G., Sarwal, M.M., 2014. Optimization for peptide sample preparation for urine peptidomics. Clin. Proteomics. https://doi.org/10.1186/1559-0275-11-7

Siless, G.E., Gallardo, G.L., Rodriguez, M.A., Rincón, Y.A., Godeas, A.M., Cabrera, G.M., 2018. Metabolites from the Dark Septate Endophyte Drechslera sp. Evaluation by LC/MS and Principal Component Analysis of Culture Extracts with Histone Deacetylase Inhibitors. Chem. Biodivers. https://doi.org/10.1002/cbdv.201800133

Singh, A., Tandon, S., Nandi, S.P., Kaur, T., Tandon, C., 2021. Downregulation of inflammatory mediators by ethanolic extract of Bergenia ligulata (Wall.) in oxalate injured renal epithelial cells. J. Ethnopharmacol. https://doi.org/10.1016/j.jep.2021.114104

Sun, Y., Li, W., Fitzloff, J.F., Van Breemen, R.B., 2005. Liquid chromatography/electrospray tandem mass spectrometry of terpenoid lactones in Ginkgo biloba. J. Mass Spectrom. https://doi.org/10.1002/jms.795

Taoka, M., Nobe, Y., Hori, M., Takeuchi, A., Masaki, S., Yamauchi, Y., Nakayama, H., Takahashi, N., Isobe, T., 2015. A mass spectrometry-based method for comprehensive quantitative determination of post-transcriptional RNA modifications: The complete chemical structure of Schizosaccharomyces pombe ribosomal RNAs. Nucleic Acids Res. https://doi.org/10.1093/nar/gkv560

Tozaki, T., Karasawa, K., Minamijima, Y., Ishii, H., Kikuchi, M., Kakoi, H., Hirota, K.I., Kusano, K., Nagata, S.I., 2018. Detection of phosphorothioated (PS) oligonucleotides in horse plasma using a product ion (m/z 94.9362) derived from the PS moiety for doping control. BMC Res. Notes. https://doi.org/10.1186/s13104-018-3885-5

Tuli, L., Ressom, H.W., 2009. LC-MS based detection of differential protein expression. J. Proteomics Bioinforma. https://doi.org/10.4172/jpb.1000102

Zahiruddin, S., Parveen, A., Khan, W., Parveen, R., Ahmad, S., 2021. TLC-Based Metabolite Profiling and Bioactivity-Based Scientific Validation for Use of Water Extracts in AYUSH Formulations 2021.

Zhou, B., Xiao, J.F., Tuli, L., Ressom, H.W., 2012. LC-MS-based metabolomics. Mol. Biosyst. https://doi.org/10.1039/c1mb05350g